Breakthrough trial offers new hope for cystic fibrosis patients
Enterprise Therapeutics' ETD001, an inhaled ENaC blocker, shows promise in Phase 2 trials for cystic fibrosis treatment, potentially improving lung function and mucus hydration.
© Copyright 2024. All Rights Reserved by MedPath